 |
|
UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies
August 05, 2008CHAPEL HILL - In the budding field of nanotechnology, scientists already know that size does matter.
But now, researchers at the University of North Carolina at Chapel Hill have shown that shape matters even more - a finding that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity.
A team of researchers led by Joseph DeSimone, Ph.D., Chancellor's Eminent Professor of Chemistry in UNC's College of Arts and Sciences and William R. Kenan, Jr. Distinguished Professor of Chemical Engineering at North Carolina State University, and Stephanie Gratton, a graduate student in DeSimone's lab, have demonstrated that nanoparticles designed with a specific shape, size and surface chemistry are taken up into cells and behave differently within cells depending on these attributes.
Their findings appear in this week's online early edition of the journal PNAS, the Proceedings of the National Academy of Sciences.
Using nanoparticles to combat cancer is an area of interest for many researchers. For decades, treating the disease has mostly involved injecting patients with toxic drugs - a practice in which only a fraction of the drugs reach the intended target, killing healthy cells in the process and causing harmful side effects.
Previous studies have shown that drug-carrying nanoparticles can hone-in on and attack tumors, in part because of their extremely small size - less than 100 nanometers (one nanometer = one billionth of a meter) - which helps allow them to pass through cell membranes. However, up until now, existing techniques have meant that targeting agents could only be delivered using spherical or granular shaped particles.
Using PRINT® (Particle Replication in Non-wetting Templates) technology - a technique invented in DeSimone's lab that allows scientists to design and produce "custom-made" nanoparticles - the UNC researchers made particles with specific shapes, sizes and surface charges. DeSimone said the aim is to optimize particle attributes for specific therapeutic objectives.
"This would mean that we could deliver lower dosages of drugs to specific cells and tissues in the body and actually be more effective in treating the cancer," said DeSimone, who is also a member of UNC's Lineberger Comprehensive Cancer Center and the co-principal investigator for the Carolina Center for Cancer Nanotechnology Excellence.
Creating particles of different dimensions, the UNC researchers changed one variable at a time, and experimented with different surface chemistries. They then incubated the different particles with human cervical carcinoma epithelial (HeLa) cells, monitoring each type to see which ones the cells absorbed most effectively.
For instance, the scientists discovered that long, rod-shaped particles (diameter, 150 nanometers; height, 450 nanometers) were internalized by cells approximately four times faster than lower aspect ratio particles (diameter, 200 nanometers; height, 200 nanometers), and traveled significantly further into the cells as well.
Gratton noted the same phenomenon is found in natural organisms.
"The long rod-shaped structure of bacteria may help explain why PRINT® particles of higher aspect ratios are internalized more rapidly and effectively than lower aspect ratio particles," she said. "If we can design particles that rely on the same mechanisms that nature has perfected for bacteria, we may unlock the key for delivering therapeutics more efficiently and effectively to treat and cure disease."
Liquidia Technologies, a UNC spin-off company, has an exclusive license to the PRINT® technology and is developing engineered nanoparticles for delivery of nucleic acids and small molecule therapeutics. Liquidia also sponsors research in the DeSimone lab. The company's chief executive officer, Neal Fowler, said the study's findings should prove of interest to the biopharmaceutical industry.
"We are delighted to contribute to the important work that Professor DeSimone and his students are undertaking in the field of nanomedicine. This work answers key questions about the role of particle shape and size that industry leaders have been asking for some time," Fowler said.
University of North Carolina at Chapel Hill
Their findings appear in this week's online early edition of the journal PNAS, the Proceedings of the National Academy of Sciences.
Using nanoparticles to combat cancer is an area of interest for many researchers. For decades, treating the disease has mostly involved injecting patients with toxic drugs - a practice in which only a fraction of the drugs reach the intended target, killing healthy cells in the process and causing harmful side effects.
Previous studies have shown that drug-carrying nanoparticles can hone-in on and attack tumors, in part because of their extremely small size - less than 100 nanometers (one nanometer = one billionth of a meter) - which helps allow them to pass through cell membranes. However, up until now, existing techniques have meant that targeting agents could only be delivered using spherical or granular shaped particles.
Using PRINT® (Particle Replication in Non-wetting Templates) technology - a technique invented in DeSimone's lab that allows scientists to design and produce "custom-made" nanoparticles - the UNC researchers made particles with specific shapes, sizes and surface charges. DeSimone said the aim is to optimize particle attributes for specific therapeutic objectives.
"This would mean that we could deliver lower dosages of drugs to specific cells and tissues in the body and actually be more effective in treating the cancer," said DeSimone, who is also a member of UNC's Lineberger Comprehensive Cancer Center and the co-principal investigator for the Carolina Center for Cancer Nanotechnology Excellence.
Creating particles of different dimensions, the UNC researchers changed one variable at a time, and experimented with different surface chemistries. They then incubated the different particles with human cervical carcinoma epithelial (HeLa) cells, monitoring each type to see which ones the cells absorbed most effectively.
For instance, the scientists discovered that long, rod-shaped particles (diameter, 150 nanometers; height, 450 nanometers) were internalized by cells approximately four times faster than lower aspect ratio particles (diameter, 200 nanometers; height, 200 nanometers), and traveled significantly further into the cells as well.
Gratton noted the same phenomenon is found in natural organisms.
"The long rod-shaped structure of bacteria may help explain why PRINT® particles of higher aspect ratios are internalized more rapidly and effectively than lower aspect ratio particles," she said. "If we can design particles that rely on the same mechanisms that nature has perfected for bacteria, we may unlock the key for delivering therapeutics more efficiently and effectively to treat and cure disease."
Liquidia Technologies, a UNC spin-off company, has an exclusive license to the PRINT® technology and is developing engineered nanoparticles for delivery of nucleic acids and small molecule therapeutics. Liquidia also sponsors research in the DeSimone lab. The company's chief executive officer, Neal Fowler, said the study's findings should prove of interest to the biopharmaceutical industry.
"We are delighted to contribute to the important work that Professor DeSimone and his students are undertaking in the field of nanomedicine. This work answers key questions about the role of particle shape and size that industry leaders have been asking for some time," Fowler said.
University of North Carolina at Chapel Hill
More Nanomedicine Therapies Current Events and Nanomedicine Therapies News Articles
|
Combating Cancer: Diagnosis, Therapy and Nanomedicine by H.D. Kumar and Swati Kumar (Author) | |
 |
Artificial Cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, and Cell/Stem Cell Therapy (Regenerative Medicine, Artificial Cells and Nanomedicine) by Thomas Ming Swi Chang (Author) This is the first book that provides a comprehensive review of the entire area of artificial cells. The author, a pioneer of the field, invented the first artificial cells some 50 years ago and has continued to carry out active research in this field. Since then, there have been explosive research activities around the world on artificial cells, especially in fields related to biotechnology, nanomedicine, cell therapy, blood substitutes, drug delivery and others. However, instead of the term artificial cells, many authors use other terminologies such blood substitutes, bioencapsulation, liposomes, nanoparticles, and so on. As a result, any meaningful literature search for a complete idea of the present status of the whole field of artificial cells is impossible. Furthermore, the fact... |
|
Present and Future Therapies for End-stage Renal Disease (Regenerative Medicine, Artificial Cells and Nanomedicine) by Eli A. Friedman (Editor), Mary C. Mallappallil (Editor) Written by an interdisciplinary team of experts, this book contains historical information as well as current update on renal replacement therapy. New technology and techniques are presented in a concise, easy-to-read style that keeps the reader interested. The contributors include physicians who practise uremia therapy since its conception to more recent graduates, along with surgeons, pioneers and physicians who are patients themselves, thus giving readers the broadest perspective. The aim of the book is to update the reader on renal replacement therapy as of 2009. It is a textbook that can be read cover to cover and still serve as a fine reference guide. The book is targeted at anyone interested in kidney replacement therapy, from students and patients to the professorial level. |
| © 2009 BrightSurf.com |